G1 Therapeutics Stock Market Value
| GTHX Stock | USD 3.99 0.13 3.37% |
| Symbol | GTHX |
G1 Therapeutics Price To Book Ratio
Is G1 Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of G1 Therapeutics. If investors know GTHX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about G1 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.93) | Revenue Per Share 1.595 | Quarterly Revenue Growth 0.451 | Return On Assets (0.16) | Return On Equity (0.92) |
The market value of G1 Therapeutics is measured differently than its book value, which is the value of GTHX that is recorded on the company's balance sheet. Investors also form their own opinion of G1 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is G1 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because G1 Therapeutics' market value can be influenced by many factors that don't directly affect G1 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between G1 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if G1 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, G1 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
G1 Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to G1 Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of G1 Therapeutics.
| 06/08/2022 |
| 04/28/2024 |
If you would invest 0.00 in G1 Therapeutics on June 8, 2022 and sell it all today you would earn a total of 0.00 from holding G1 Therapeutics or generate 0.0% return on investment in G1 Therapeutics over 690 days. G1 Therapeutics is related to or competes with Allogene Therapeutics, Heron Therapeuti, AnnexonInc, Sangamo Therapeutics, X4 Pharmaceuticals, Hookipa Pharma, and Mereo BioPharma. G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercial... More
G1 Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure G1 Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess G1 Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 10.98 | |||
| Information Ratio | 0.0623 | |||
| Maximum Drawdown | 66.04 | |||
| Value At Risk | (5.61) | |||
| Potential Upside | 12.35 |
G1 Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for G1 Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as G1 Therapeutics' standard deviation. In reality, there are many statistical measures that can use G1 Therapeutics historical prices to predict the future G1 Therapeutics' volatility.| Risk Adjusted Performance | 0.054 | |||
| Jensen Alpha | 0.194 | |||
| Total Risk Alpha | (0.55) | |||
| Sortino Ratio | 0.0549 | |||
| Treynor Ratio | 0.1107 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of G1 Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
G1 Therapeutics Backtested Returns
G1 Therapeutics appears to be very risky, given 3 months investment horizon. G1 Therapeutics retains Efficiency (Sharpe Ratio) of 0.0383, which attests that the company had a 0.0383% return per unit of price deviation over the last 3 months. We have found thirty technical indicators for G1 Therapeutics, which you can use to evaluate the volatility of the entity. Please utilize G1 Therapeutics' Market Risk Adjusted Performance of 0.1207, semi deviation of 10.59, and Standard Deviation of 9.68 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, G1 Therapeutics holds a performance score of 2. The firm owns a Beta (Systematic Risk) of 6.16, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, G1 Therapeutics will likely underperform. Please check G1 Therapeutics' value at risk, and the relationship between the standard deviation and kurtosis , to make a quick decision on whether G1 Therapeutics' current price history will revert.
Auto-correlation | -0.67 |
Very good reverse predictability
G1 Therapeutics has very good reverse predictability. Overlapping area represents the amount of predictability between G1 Therapeutics time series from 8th of June 2022 to 19th of May 2023 and 19th of May 2023 to 28th of April 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of G1 Therapeutics price movement. The serial correlation of -0.67 indicates that around 67.0% of current G1 Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.67 | |
| Spearman Rank Test | -0.27 | |
| Residual Average | 0.0 | |
| Price Variance | 1.05 |
G1 Therapeutics lagged returns against current returns
Autocorrelation, which is G1 Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting G1 Therapeutics' stock expected returns. We can calculate the autocorrelation of G1 Therapeutics returns to help us make a trade decision. For example, suppose you find that G1 Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
G1 Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If G1 Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if G1 Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in G1 Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
G1 Therapeutics Lagged Returns
When evaluating G1 Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of G1 Therapeutics stock have on its future price. G1 Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, G1 Therapeutics autocorrelation shows the relationship between G1 Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in G1 Therapeutics.
Regressed Prices |
| Timeline |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out G1 Therapeutics Correlation, G1 Therapeutics Volatility and G1 Therapeutics Alpha and Beta module to complement your research on G1 Therapeutics. For more information on how to buy GTHX Stock please use our How to Invest in G1 Therapeutics guide.Note that the G1 Therapeutics information on this page should be used as a complementary analysis to other G1 Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for GTHX Stock analysis
When running G1 Therapeutics' price analysis, check to measure G1 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy G1 Therapeutics is operating at the current time. Most of G1 Therapeutics' value examination focuses on studying past and present price action to predict the probability of G1 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move G1 Therapeutics' price. Additionally, you may evaluate how the addition of G1 Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |
G1 Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.